Contrave (Naltrexone/Bupropion)
Contrave Extended-Release (Naltrexone/Bupropion Combination)
FDA-approved weight management medication combining naltrexone (opioid antagonist) and bupropion (antidepressant). Targets the brain's reward system and appetite control center. An oral, non-GLP-1 option for weight management.
📊 Evidence by Outcome
Modest weight loss (5-10%)
3 studies • Consistency: Moderate • Effect: Moderate
Reduced food cravings
3 studies • Consistency: Moderate • Effect: Moderate
Appetite suppression
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 1 Citations
COR-I Trial: Contrave for Obesity
••2010
Key Finding: Contrave produced significantly greater weight loss (6.1-8.1%) than placebo (1.3%) at 56 weeks
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
$100-400/month
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.